First approval for Kyowa Kirin's lead biologic, for ATL in Japan
This article was originally published in Scrip
Kyowa Hakko Kirin has received the first approval worldwide for its lead therapeutic biologic, in Japan for the chemokine [C-C motif] receptor 4-targeting antibody Poteligeo (mogamulizumab; KW-0761).
You may also be interested in...
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.
AbbVie Japan has seen strong growth for its commercial and R&D portfolios over the past few years, but with flagship product Humira facing its first local biosimilar competition, the company is looking to brand strength and an increased oncology presence to address the challenge.
Japan’s regulators have approved a large batch of new products, including a novel antibody from Chugai, world-first nods for the country’s second HIF-PH inhibitor and an asthma therapy, and the first Humira biosimilar in Japan – as well as five drugs from Novartis.